Drug combination shows meaningful responses for malignant peritoneal mesothelioma patient
A phase II study found that treatment with atezolizumab and bevacizumab was well-tolerated and resulted in a 40% objective response rate in patients with advanced malignant peritoneal mesothelioma,…
